Sanomics Limited opens in Bangkok as gateway to the ASEAN region, and became the first Hong Kong biotechnology start-up to launch in Thailand.
The opening ceremony in January was led by Sanomics Chairman, Professor Dr. Tony Mok, and was attended by Dr Sunny Chai, BBS, Board Chairman of Hong Kong Science and Technology Parks Corporation, Mr Peter Wong, Regional Director for Southeast Asia and South Asia, Hong Kong Trade Development Council, as well as Hong Kong and Thailand renowned leaders in cancer research.
Established in Hong Kong Science and Technology Parks Corporation (HKSTP) in 2015, Sanomics Limited is a Hong Kong based biotechnology start-up that specialises in liquid biopsy and tissue-based genomic diagnostics for cancer patients.
The company is the first Hong Kong biotechnology start-up launched in Thailand after Mrs Carrie Lam, GBM, GBS, Chief Executive of HKSAR’s visit with Prime Minister of Thailand, Mr Prayut Chan-o-cha, in August 2017 to form closer ties between Thailand and Hong Kong.
Thanks to Thailand Government’s “Thailand 4.0” initiative, Sanomics successfully applied for Board of Investment (BOI) company registration with contribution of biotechnology technology transfer in conducting genomic diagnostic in cancer precision medicine, which is the business promoted by BOI.
“Patient First” - Accurate, speedy and affordable genomic diagnostics
“Patient First is our principle. Targeted therapy works only on specific types of tumour growth and requires detailed genetic tests for a doctor to determine if it is applicable. Our mission is to help patients avoid wasting time and money on an ineffective treatment. Leveraging Belt and Road Initiative and answering the strong demand of cancer screening tests in Thailand, we have chosen Bangkok to be the first stop of our expansion in ASEAN and we are committed to provide our best service here” said Mr Stanley Sy, CEO of Sanomics Limited.
The opening ceremony in January was led by Sanomics Chairman, Professor Dr. Tony Mok, and was attended by Dr Sunny Chai, BBS, Board Chairman of Hong Kong Science and Technology Parks Corporation, Mr Peter Wong, Regional Director for Southeast Asia and South Asia, Hong Kong Trade Development Council, as well as Hong Kong and Thailand renowned leaders in cancer research.
Established in Hong Kong Science and Technology Parks Corporation (HKSTP) in 2015, Sanomics Limited is a Hong Kong based biotechnology start-up that specialises in liquid biopsy and tissue-based genomic diagnostics for cancer patients.
The company is the first Hong Kong biotechnology start-up launched in Thailand after Mrs Carrie Lam, GBM, GBS, Chief Executive of HKSAR’s visit with Prime Minister of Thailand, Mr Prayut Chan-o-cha, in August 2017 to form closer ties between Thailand and Hong Kong.
Thanks to Thailand Government’s “Thailand 4.0” initiative, Sanomics successfully applied for Board of Investment (BOI) company registration with contribution of biotechnology technology transfer in conducting genomic diagnostic in cancer precision medicine, which is the business promoted by BOI.
“Patient First” - Accurate, speedy and affordable genomic diagnostics
“Patient First is our principle. Targeted therapy works only on specific types of tumour growth and requires detailed genetic tests for a doctor to determine if it is applicable. Our mission is to help patients avoid wasting time and money on an ineffective treatment. Leveraging Belt and Road Initiative and answering the strong demand of cancer screening tests in Thailand, we have chosen Bangkok to be the first stop of our expansion in ASEAN and we are committed to provide our best service here” said Mr Stanley Sy, CEO of Sanomics Limited.
